Sweet Annie (Artemisia annua L.): A Comprehensive Reference
1. Identity and Botanical Profile
Names and Classification
Artemisia annua L., also referred to as sweet wormwood, sweet annie, sweet sagewort, and annual wormwood (Chinese: qīnghāo), is a species of wormwood native to temperate Asia but naturalized worldwide, and is a member of the family Asteraceae. Botanical synonyms include Artemisia chamomilla, and the plant is also known by the Chinese names Huang Hua Hao and Li Hao. Its Chinese name Qing Hao is often translated as "green grass."
Physical Description and Origin
Sweet Annie is a common type of wormwood native to temperate Asia, but naturalized in many countries including scattered parts of North America. It occurs naturally as part of steppe vegetation in the northern parts of Chahar and Suiyuan provinces in China, at 1,000 to 1,500 m above sea level. The plant belongs to the Asteraceae family and is an annual short-day plant. Its stem is erect and brownish or violet-brown, and the plant itself is hairless. It naturally grows from 30 to 100 cm tall, although in cultivation plants can reach a height of 200 cm. It is in flower from August to September, and the seeds ripen from September to October.
Plant Parts Used
The parts used are the leaves and flowering stems from the top of the plant, cut at one-third of the mature plant's height. The bottom leaves contain approximately half the artemisinin concentration found in the tops, which plays an important role in the efficiency of preparations made from the herb. The official raw material recognized in pharmacopeias is the dried leaves of A. annua, Artemisia annuae folium, which has a monograph in both the Chinese Pharmacopoeia and the Vietnamese Pharmacopoeia. According to these documents, the leaves should be standardized for artemisinin content, which cannot be lower than 0.7% of dry weight.
Common Forms and Preparations
Artemisia annua has been traditionally used in various forms including fresh leaves, dried herb, tincture, powder, essential oil, and capsules. It can be prepared through methods such as brewing into tea, decocting for stronger extracts, making infusions, or applying topically for localized effects. Preparations documented historically in Chinese texts include juice from crushed leaves, decoctions at approximately 30 g per day, tablets, dried leaves in powder form at 3 g per day for 5 days, fresh plants at 3 g per day, and Qing Hao wine.
2. Traditional and Historical Use
Chinese Medicine (the Primary Tradition)
Artemisia annua has more than 2,000 years of history in the treatment of diseases. Since its first record in the Mawangdui texts (Wu Shi Er Bing Fang) from 168 BCE, it has been mentioned in different ancient medical treatises. Traditionally, this herb was used for respiratory infections, wound healing, longevity, fevers, and notably "intermittent fevers."
The physician-philosopher Ge Hong was the first to prominently mention the anti-fever properties of these plants in his "Manual of Prescriptions for Emergency Treatment" in the early 4th century. His recorded method of preparation was a cold water extraction: a handful of the aerial parts of the plant was soaked in approximately 1–2 liters of water, and the juice was drunk in its entirety.
The use of Artemisia annua as a major medicine for intermittent fevers (consistent with what is now recognized as malaria) became prominent during the Song Dynasty (960–1279). The decoction of Qing Hao was described in the "General Medical Collection of the Royal Benevolence." The expansion of rice fields at that time increased the ideal breeding grounds for mosquitoes carrying the malaria parasite, which likely drove the increased use of this remedy.
Its preparation for paroxysmal malarial fever was recommended in the renowned book Compendium of Materia Medica by Li Shizhen. In Chinese literature, its scientific name Artemisia annua was formally assigned in the twentieth century with the publication of the First Chinese Pharmacopoeia in 1930.
The most common ethnobotanical usage of this plant involves the use of whole-plant decoction for the treatment of cold, malaria, and cough. The whole flowering plant is described ethnobotanically as antipyretic, antihelminthic, antispasmodic, antiseptic, and antimalarial.
Discovery of Artemisinin and the Nobel Prize
After the discovery of its antimalarial potential by Prof. Tu Youyou in 1972, the World Health Organization recommended A. annua as an antimalarial. The discovery of artemisinin and its antimalarial properties made Chinese scientist Tu Youyou the recipient of the 2011 Lasker Prize and the 2015 Nobel Prize in Physiology or Medicine. Nobel laureate Tu Youyou explains that in Traditional Chinese Medicine, Qing Hao is the generic name for a category of medicinal herbs (mugwort), containing six varieties, each with different chemical components and different degrees of efficacy in treating malaria. Only Artemisia annua L. has proven strong anti-malarial activity.
3. Key Constituents and Active Compounds
Artemisinin and Sesquiterpenoids
A. annua is a medicinal plant that is widely distributed around the world and contains many types of chemical composition. Studies have shown that A. annua contains more than 100 types of chemical constituents, with a rich intra-species biodiversity in both proportion and abundance of secondary metabolites.
The antimalarial activity of this plant is primarily due to artemisinin, a sesquiterpene lactone containing an endoperoxide moiety that acts as the key pharmacophore. The sesquiterpenoid constituents include artemisinin and numerous related compounds and derivatives — Artemisinin 1, 2, 3, 4, and 5, artemisic acid, epoxyarteannuinic acid, artemisinol, and others — alongside flavonoids, polyphenols, coumarins, and phenolic acids.
One gram of dried powder of the aerial parts of Sweet Wormwood contains 0.1 to 8 mg of artemisinin, a range that reflects the significant geographic and environmental variation in secondary metabolite production. Plants within the same species show few differences in morphology, but they present significant variation in secondary metabolites based on their geographical locations, as a result of genetic and environmental interaction.
Volatile Oil Constituents
The essential oil constituents consist of 6–76% artemisia ketone, up to 44% camphor, up to 33% germacrene D, up to 16% alpha-pinene, and up to 15% alpha-guaiene. The essential oil derived from the leaves has been shown to have antioxidant, antibacterial, and antifungal properties.
Flavonoids and Phenolic Compounds
The main constituents of pharmacological interest in Artemisia annua include artemisinin and its derivatives, quercetin, and polyphenols. Research has shown that the combination of artemisinin, scopoletin, arteannuin B, and arteannuic acid has antimalarial effect, while the combination of scopoletin, arteannuin B, and arteannuic acid is conducive to resolving summerheat-heat in traditional Chinese medical terms.
4. Established Mechanisms of Action
Antimalarial Mechanism
A lactone ring in artemisinin's molecular structure is formed by connecting two carbon atoms via a peroxy bond. This peroxy bond is the key to the antimalarial action of artemisinin molecules. Research has demonstrated that dihydroartemisinin (DHA), the clinically relevant active metabolite, kills parasites via a two-pronged mechanism: causing protein damage and compromising parasite proteasome function. The consequent accumulation of proteasome substrates — unfolded/damaged and polyubiquitinated proteins — activates the ER stress response and underpins DHA-mediated killing.
Additional mechanisms of action attributed to artemisinin include interference with parasite transport proteins, disruption of parasite mitochondrial function, modulation of host immune function, and inhibition of angiogenesis.
Anticancer Mechanisms (Preclinical)
Mechanistically, artemisinin and its derivatives exert antitumor effects in preclinical models by inducing oxidative stress, arresting the cell cycle, triggering apoptosis, and inhibiting angiogenesis. They likewise modulate immune responses, re-establishing immune homeostasis and potentially enhancing the effectiveness of immunotherapeutic strategies.
Key signaling pathways modulated by active constituents of A. annua in cancer-related research include PI3K/AKT, JAK-STAT, p53, and GPX4, with effects on the immune and tumor microenvironment reported in experimental settings.
Anti-inflammatory and Immunomodulatory Mechanisms
Artemisinin and its derivatives, initially studied for immunomodulatory effects in the early 2000s, showed promise in treating autoimmune and inflammatory diseases. Recent findings have revealed their ability to modulate vital immune cells, including T cells, B cells, macrophages, and NK cells.
Role of the Whole Plant Matrix
Animal studies have revealed that the antimalarial effect of whole-plant A. annua extracts was approximately 10-fold higher than that of artemisinin alone when administered at the same dosage. Pharmacokinetic analysis showed that whole-plant extracts exhibited significantly enhanced oral bioavailability, a longer half-life, and extended mean retention time in rats compared to pure artemisinin. Flavonoids present in the plant have been shown to enhance the antimalarial activity of artemisinin, suggesting that the complex matrix of chemicals in A. annua may work in conjunction with artemisinin.
5. Scientific Evidence by Area of Use
5.1 Malaria
Evidence strength: Strong (for artemisinin-based combination therapies / ACTs); Preliminary to Moderate (for whole-plant preparations).
Artemisinin and its derivatives have high efficiency, quick effects, and low toxicity in malaria treatment and have become the first-choice treatment, especially for falciparum malaria. The World Health Organization (WHO) recommends artemisinin-based combination treatments (ACTs) as the first-line treatment for uncomplicated Plasmodium falciparum malaria and chloroquine-resistant P. vivax malaria.
In wide-scale clinical trials, pure artemisinin showed poor pharmacokinetic properties but nonetheless demonstrated potent antimalarial activity with a high safety profile. It was determined that artemisinin modified to artesunate or artemether improved bioavailability and was more effective when used in combination with other antimalarial drugs, mainly mefloquine, which became known as Artemisinin Combination Therapy (ACT).
Artemisinin's clinical value as a single purified compound was initially limited by various deficiencies, such as its poor solubility, poor stability, low oral bioavailability, and short plasma half-life. Various efficient semisynthetic artemisinin derivatives, such as dihydroartemisinin, artemether, and artesunate, were subsequently developed.
Whole-plant preparations: A preclinical study (rodent model) found that a single dose of whole-plant A. annua (containing 24 mg/kg artemisinin) reduced parasitemia more effectively than a comparable dose of purified drug. This increased efficacy may result from a documented 40-fold increase in the bioavailability of artemisinin in the blood of mice fed the whole plant, compared to those administered synthetic drug. Synergistic benefits may derive from the presence of other anti-malarial compounds in A. annua.
In a clinical trial study, dried leaves of A. annua gave 40-fold less artemisinin than was required with pure artemisinin to achieve comparable effects. In an animal study, the whole plant was found to be more effective than a comparable dose of pure artemisinin, and the data suggest that the whole plant preparation overcomes existing resistance to pure artemisinin.
With the wide application of artemisinin-based medicines, malaria parasites have developed artemisinin resistance, making malaria prevention and control increasingly challenging. Artemisinin-resistant Plasmodium strains have been found in many countries and regions.
5.2 Arthritis (Osteoarthritis and Rheumatoid Arthritis)
Evidence strength: Preliminary to Moderate (small clinical trials; more large-scale trials needed).
A pilot randomized, placebo-controlled clinical trial investigated the safety and efficacy of a dietary supplement containing an extract from Artemisia annua (Arthrem) on pain, stiffness, and functional limitation in osteoarthritis (OA) of the hip or knee. Forty-two patients were randomized into three groups (n=14 each): 150 mg extract twice daily (low dose), 300 mg twice daily (high dose), or placebo twice daily, administered over 12 weeks. Efficacy was assessed using the WOMAC® index and a visual analog scale (VAS) for pain. Participants treated with the low-dose arm demonstrated significant improvement in WOMAC total scores from baseline to 12 weeks (mean change –12.2; SD 13.84; p=0.0159), whereas improvement was not shown in the placebo group. Treatment with 150 mg twice daily was associated with clinically relevant reductions in pain over 12 weeks, and the extract showed potential as an anti-inflammatory/analgesic in OA.
A randomized controlled clinical trial investigated the effect and safety of the extract of Artemisia annua L. (EAA) as a complementary treatment for active rheumatoid arthritis (RA). All 159 participants with active RA were randomly assigned to a control group (80 cases) or EAA group (79 cases). Control group patients were medicated with leflunomide and methotrexate for 48 weeks; EAA group patients received leflunomide, methotrexate, plus EAA at 30 g/day. In this study, people with active rheumatoid arthritis treated with the antirheumatic drug combination plus Artemisia annua extract showed lower levels of a marker of inflammation (ESR) than those treated with leflunomide and methotrexate alone.
Many in vivo experiments in disease-relevant animal models demonstrate therapeutic efficacy of artemisinin-type drugs against rheumatic diseases, including rheumatoid arthritis, osteoarthritis, lupus erythematosus, arthrosis, and gout, as well as lung diseases and skin diseases. However, large-scale, well-powered randomized clinical trials in humans remain limited.
5.3 Oncology (Cancer)
Evidence strength: Preclinical only for most indications; very limited and early-stage human clinical data.
Artemisinin and its derivatives have demonstrated antitumor activity against a variety of malignancies in preclinical research, including leukemia, ovarian cancer, glioblastoma, prostate cancer, and melanoma. These mechanisms include the induction of oxidative stress, cell cycle arrest, apoptosis, autophagy, and inhibition of angiogenesis.
Both in vitro and in vivo clinical trials and case reports have shown promising activity of artemisinin drug derivatives in treating certain types of cancer. However, the reported articles are few and therefore not statistically significant. The minimal toxicity shown in clinical trials and case reports, along with the selective cytotoxic activity of the compounds, make them possible cancer therapies due to the emerging evidence of effectiveness.
Preclinical (lab or animal) studies have shown some anticancer effects, but clinical evidence in humans is extremely limited.
5.4 Autoimmune and Inflammatory Diseases
Evidence strength: Mostly preclinical; some early human trial data for RA and SLE; ongoing multicenter trials.
Artemisia annua has been widely used to treat autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis, primarily in the context of Traditional Chinese Medicine. Phytocompounds from A. annua, such as artemisinin and artesunate, have found their way into modern research and the treatment of malaria, rheumatoid arthritis, systemic lupus erythematosus (SLE), and allergic contact dermatitis.
Ongoing multicenter randomized clinical trials are investigating the effects of these compounds on rheumatic, inflammatory, and autoimmune diseases, with the aim of translating promising preclinical data into clinical applications.
5.5 Liver Function
Evidence strength: Preliminary (a single randomized controlled study reported).
One human clinical study aimed to demonstrate that SPB-201 (a powdered-water extract of Artemisia annua) can improve liver function in subjects with non-alcoholic liver dysfunction at mild to moderate levels. The study observed a decrease of 271% in aspartate aminotransferase (AST) level and a significant decrease of 334% in alanine aminotransferase (ALT) level in the test group compared to the control group at 4-week follow-up. After 8 weeks, decreases of 199% in AST and 216% in ALT were reported in the test group compared to the control group, confirming that SPB-201 intake significantly enhanced liver function and health. These results must be interpreted with caution given the limited scale of the study.
5.6 Other Parasitic Infections
Artemisinin derivatives are the most recent single drugs approved and introduced for public antimalarial treatment. Although their recommended use is for the treatment of Plasmodium falciparum infection, these drugs also act against other parasites, as well as against tumor cells. Evidence for efficacy against other parasites (such as Leishmania, Trypanosoma) is primarily in vitro and animal-based.
6. Body Systems and Health Areas Associated
- Immune system: Artemisia annua is commonly used for its anti-malarial, immunosuppressive, and anti-inflammatory properties.
- Musculoskeletal / Rheumatological: Artemisia extracts show benefits for pain and other symptoms of arthritis in clinical studies.
- Hepatic (Liver): Artemisinin and its derivatives have been reported as effective in the treatment of various pathogenic diseases, and preclinical models suggest hepatoprotective effects in some contexts.
- Oncology: Artemisiae Annuae Herba is gaining recognition for its anti-cancer potential due to the unique structures and biological effects of its constituents, although this remains largely preclinical.
- Gastrointestinal: Historically, A. annua has been considered useful in the management of fever from viral and bacterial infections, dysentery, the common cold, fungal infections, and digestive problems including loss of appetite.
- Dermatological: It has been traditionally used for skin diseases, especially systemic lupus erythematosus, psoriasis, and eczema.
7. Dosage Forms and Reported Dosages
The following dosages appear in the peer-reviewed literature or pharmacopeial documents and are reported here as they appear in the sources, without endorsement.
- Osteoarthritis (clinical trial): 150 mg or 300 mg of Artemisia annua extract (as Arthrem) twice daily for 12 weeks.
- Rheumatoid arthritis (clinical trial, as adjunct): 30 g/day of Artemisia annua extract added to standard disease-modifying antirheumatic drug therapy for 48 weeks.
- Allergic rhinitis (clinical study): Sublingual drops of glycerinated pollen extracts of Artemisia annua at a dosage of 2,400 biological units daily for up to 32 weeks were used in one clinical study addressing allergic rhinitis.
- Severe malaria (resistant cases, dried leaf preparation): Dried leaf A. annua dosed at 500 mg twice daily for 5 days was evaluated in a study of patients with severe malaria resistant to previous artemisinin therapies.
- Chinese Pharmacopoeia (traditional adult reference): Documented historical preparations include dried leaves in powder form at a dose of 3 g per day for 5 days, and fresh plants at a dose of 3 g per day.
- Standardization standard: According to the Chinese and Vietnamese pharmacopeias, leaves should be standardized for artemisinin content, which cannot be lower than 0.7% of dry weight.
- General supplement use (extract, arthritis): In clinical research, 150–300 mg of Artemisia annua extract twice daily has been used for up to 9 months for symptoms of arthritis.
8. Safety Considerations and Drug Interactions
Hepatotoxicity
An A. annua extract produced using a supercritical carbon dioxide extraction method and formulated with grapeseed oil was marketed in New Zealand as a natural product for joint health. As of January 31, 2019, the New Zealand Pharmacovigilance Centre had received 29 reports of hepatic adverse reactions occurring in patients taking this extract. Patients were aged 47 to 93 years (median 67). Time to onset of hepatotoxicity from starting the extract was 7 days to approximately 12 months in the 23 reports with this information, and 19 of those reports indicated onset within 12 weeks. The A. annua extract was the sole suspect medicine in 27 of the reports.
Several artemisinin derivatives have been linked to rare instances of acute liver injury. Complicating the interpretation of reports, most severe cases of liver injury occurred in patients who were also receiving other antimalarial agents, some of which are known to be hepatotoxic. Clinically apparent liver injury due to artemisinin derivatives is very rare and was not reported in several large clinical trials of malaria treatment. Most published reports of hepatotoxicity of artemisinin were linked to use of herbal supplements containing artemisinin and with extended treatment.
Pregnancy and Embryotoxicity
Animal studies of Artemisia annua extracts, artemisinin, and related compounds have shown the potential for both pregnancy loss (miscarriage) and developmental abnormalities in animals. These types of studies are used to identify risks for medicines used during pregnancy in humans.
The Australian Therapeutic Goods Administration (TGA) identified Artemisia annua as "high risk" due to these species containing higher levels of artemisinin. Sponsors of medicines containing A. annua were required to provide information for risk assessment. The TGA subsequently identified that certain products may expose consumers to unsafe levels of artemisinin during pregnancy when used as directed, and recalled affected products without adequate warnings. The TGA imposed conditions on all listed medicines containing A. annua requiring warnings against use during pregnancy.
Use should be avoided during the first trimester of pregnancy. Artemisinin derivatives, in particular artemether, have a toxic effect at the embryonic stage; animal studies in pregnant mice, rats, or rabbits suggest teratogenicity may be limited to early pregnancy.
Neurotoxicity Risk
The risk of cumulative neurotoxicity may prohibit the prophylactic use of artemisinin-based products. This concern has been noted in the context of high-dose or prolonged exposure rather than short therapeutic courses used in clinical trials.
CYP Enzyme Interactions and Drug Interactions
Artemisinin derivatives are extensively metabolized by the liver, primarily via CYP 3A4, and are prone to drug-drug interactions if given with strong CYP 3A4 inducers such as rifampin, phenytoin, or St. John's Wort, or inhibitors such as itraconazole or ritonavir. Clinically important effects may also occur due to potent inhibition of the CYP1A2 enzyme by artemisinin.
Gastrointestinal and Other Adverse Effects
Vomiting is the most common side effect reported among people treated with Artemisia annua tea for malaria. Clinical trial data document adverse effects with artemisinin derivatives, including gastrointestinal complaints (abdominal pain, diarrhea, nausea, vomiting), rash, cardiovascular changes (bradycardia, prolongation of the QT interval), and metabolic changes (hypoglycemia).
Essential Oil Safety
The essential oil constituents of A. annua include up to 44% camphor and high proportions of artemisia ketone. As ketones are considered possible toxins, essential oils high in ketones are used with great care or often avoided by aromatherapists. The European Food Safety Authority lists A. annua leaves as a raw material that is not health-neutral due to the high concentration of camphor (2.58–37.5%) in the composition of the oil.
WHO Position on Non-Pharmaceutical Herbal Preparations
Studies have found that dried leaves of A. annua are more efficacious than artemisinin alone in clearing malaria from the bloodstream and are more bioavailable in certain models. Whole-plant preparations have also been reported in the literature to be effective in treating patients with artesunate-resistant malaria. Nonetheless, the WHO has historically maintained cautious positions regarding the use of non-pharmaceutical, non-standardized herbal forms of A. annua for malaria treatment, citing concerns about ensuring adequate dose, quality control, and resistance management.
References
Go back